KDM1A and glioblastoma: Future studies should focus on optimizing dual LSD1/kinase inhibitors for glioblastoma, including high brain permeability, and understanding the factors that dictate whether a single-molecule approach or combination therapy will be more effective in overcoming resistance and improving efficacy.